Comparison of oral and intravenous proton pump inhibitor in patients with high risk bleeding peptic ulcers

ABSTRACT

To compare the efficacy of oral omeprazole vs intravenous omeprazole in decreasing risk of re-bleeding in peptic ulcer patients. This prospective, randomized, controlled clinical trial was conducted at Ghulam Mohammad Mahar Medical College Hospital, Sukkur, Pakistan from January 2010 to December 2011. One hindered and six patients with high risk peptic ulcer were randomized to receive either oral omeprazole [80mg BID for 3 days] or IV omeprazole [80mg bolus and 8mg/hour infusion for 3 days] followed by omeprazole [20mg each day for 30 days]. All patients underwent upper endoscopy and endoscopic therapy within 24 hours. Seventeen patients were excluded from the study. Forty four patients were randomly allocated into oral omeprazole group and 41 to IV omeprazole group. Both groups were similar for factors affecting the outcome. Bleeding reoccurred in five patients of oral omeprazole group and four patients in IV omeprazole group [11.4% vs 9.8%]. The mean hospital stay and blood transfusion were not different in both groups. Oral omeprazole and IV omeprazole had equal effects on prevention of re-bleeding after endoscopic therapy in patients with high risk bleeding peptic ulcers